Loading...
Novo Nordisk Stock Plunges 13% as Weight-Loss Drug Trails Eli Lilly Rival
LIVE TV
LOCAL
Tour
ENGLISH
For You
Entertainment
National
Sports
Markets
Business & Economy
Lifestyle
World
Astrology & Religion
Technology
Education & Jobs
Auto
Politics
Viral
Opinions
Loading more articles...
Home
Local
Live TV
Novo Nordisk Shares Plunge 13% as Weight-Loss Drug Fails to Match Eli Lilly Rival
C
CNBC TV18
•
23-02-2026, 16:24
Novo Nordisk Shares Plunge 13% as Weight-Loss Drug Fails to Match Eli Lilly Rival
•
Novo Nordisk's experimental obesity drug CagriSema did not achieve non-inferiority in weight loss compared to Eli Lilly's tirzepatide.
•
CagriSema patients recorded 23% weight loss, falling short of tirzepatide's 25.5% after 84 weeks.
•
Novo Nordisk shares tumbled over 13% in pre-market trading, hitting their lowest since July 2021.
•
Eli Lilly's shares rose 3.5% in US pre-market dealings following the news.
•
Novo plans further trials and higher-dose combinations for CagriSema amidst intensifying competition in the obesity drug market.
Read Full Article on Cnbc in English
✦
More like this
✦
More like this
Markets Log Third-Worst Weekly Fall of 2026; Nifty IT Plunges 19% in February
C
CNBC TV18
Investors Buy Dip Amid US-Iran Tensions; JPMorgan Cautious Despite Market Rebound
C
CNBC TV18
Market Crashes Second Week Amidst West Asia Tensions; Nifty Bank Sees 14-Month Low
C
CNBC Awaaz
US Stock Market Rollercoaster: Tech Plunges, Nvidia Leads Decline Amid AI Doubts
C
CNBC Awaaz
IndiGo Shares Plunge 4% as Citi Cuts Price Target Amid Geopolitical Uncertainty
C
CNBC TV18
Dalal Street Bleeds: Sensex Plunges 1,380 Pts, Nifty Below 23,150 Amid Geopolitical Tensions
C
CNBC TV18